Literature DB >> 15319776

Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen.

Rie Kojima1, Masahiro Kami, Yasuhito Nannya, Eiji Kusumi, Miwa Sakai, Yuji Tanaka, Yoshinobu Kanda, Shin-Ichiro Mori, Shigeru Chiba, Shigesaburo Miyakoshi, Kinuko Tajima, Hisamaru Hirai, Shuichi Taniguchi, Hisashi Sakamaki, Yoichi Takaue.   

Abstract

To evaluate the clinical characteristics of invasive aspergillosis (IA) after reduced-intensity stem cell transplantation (RIST) compared with those after conventional stem cell transplantation (CST), we examined the medical records of 486 CST and 178 RIST recipients. The overall incidence of IA after allogeneic transplantation was 35 (5.3%) of 664, which gave a 3-year cumulative incidence of 5.6%. The estimated 3-year incidence of IA in CST and RIST was 4.5% and 8.2% (P = .045), respectively, but the mortality rates were similar (76% and 86%). The median onset of IA after RIST (day 127) occurred significantly later than that after CST (day 97). A multivariate analysis revealed that IA was associated with age older than 50 years (relative risk, 2.12; 95% confidence interval, 1.08-4.17; P = .03) and the presence of acute and/or chronic GVHD (relative risk, 6.2; 95% confidence interval, 2.4-16.4; P = .0002). IA remains an important complication after allogeneic transplantation, regardless of the type of conditioning regimen.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15319776     DOI: 10.1016/j.bbmt.2004.06.003

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

1.  Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Rodrigo Martino; Rocio Parody; Takahiro Fukuda; Johan Maertens; Koen Theunissen; Aloysius Ho; Ghulam J Mufti; Nicolaus Kroger; Arnold R Zander; Dominik Heim; Monika Paluszewska; Dominik Selleslag; Katerina Steinerova; Per Ljungman; Simone Cesaro; Anna Nihtinen; Catherine Cordonnier; Lourdes Vazquez; Monica López-Duarte; Javier Lopez; Rafael Cabrera; Montserrat Rovira; Stefan Neuburger; Oliver Cornely; Ann E Hunter; Kieren A Marr; Hans Jürgen Dornbusch; Hermann Einsele
Journal:  Blood       Date:  2006-05-23       Impact factor: 22.113

2.  Aspergillosis in hematopoietic stem cell transplant recipients: risk factors, prophylaxis, and treatment.

Authors:  Robin K Avery
Journal:  Curr Infect Dis Rep       Date:  2009-05       Impact factor: 3.725

3.  Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study.

Authors:  Yae-Jean Kim; Ki Woong Sung; Hye Sook Hwang; Shin Han Jung; Ju Youn Kim; Eun Joo Cho; Su Jin Lim; Young Bae Choi; Hee Won Cheuh; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo
Journal:  Yonsei Med J       Date:  2011-03       Impact factor: 2.759

4.  Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.

Authors:  David I Marks; Antonio Pagliuca; Christopher C Kibbler; Axel Glasmacher; Claus-Peter Heussel; Michal Kantecki; Paul J S Miller; Patricia Ribaud; Haran T Schlamm; Carlos Solano; Gordon Cook
Journal:  Br J Haematol       Date:  2011-08-22       Impact factor: 6.998

5.  Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation.

Authors:  Satoshi Hashino; Lena Morita; Mutsumi Takahata; Masahiro Onozawa; Masao Nakagawa; Takahito Kawamura; Fumie Fujisawa; Kaoru Kahata; Koh Izumiyama; Masakatsu Yonezumi; Koji Chiba; Takeshi Kondo; Masahiro Asaka
Journal:  Int J Hematol       Date:  2007-12-11       Impact factor: 2.319

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.